Abstract Details

Title Cerebrospinal Fluid TDP-43 is a Possible Predictor of Survival in Amyotrophic Lateral Sclerosis

Topic Aging, Dementia, and Behavioral Neurology

Presentation(s) P8 - Poster Session 8 (8:00 AM-9:00 AM)

Poster/Presentation
Number 10-009

Objective

To evaluate the cerebrospinal fluid (CSF) TAR DNA-binding protein 43 (TDP-43) levels in Amyotrophic Lateral Sclerosis (ALS) patients compared to controls to investigate a possible diagnostic or prognostic value in clinical practice.

Background

The TDP-43 protein is normally expressed in many tissues, including the brain, and it has been identified as the major component of ubiquitin-positive inclusions in the brain of ALS patients.

Design/Methods 25 patients with ALS diagnosis (76% men, mean age 66 years) and 24 control subjects (42% men, mean age 57 years), attending at Center of Neurodegenerative Disease and Brain Aging of University of Bari c/o Card. Panico Hospital (Tricase), were included in the study. Controls were subjects referred to the centre for subjective cognitive complaints but without any evidence of neurological processes at the end of clinical and imaging assessment. The CSF TDP-43 levels were measured using a commercial ELISA kit (Cusabio, PR China) according to the manufacturer’s instructions. Statistical analyses were performed using R software.

Results

The mean value of CSF TDP-43 levels was 5.0 ng/mL (SD 1.9) for ASL and 2.1 ng/mL (SD 1.5) for controls. There were no differences in the CSF TDP-43 levels between sex (p=0.122), site of onset (p=0.256) and King’s staging (ranging from stage 2 to 3 for all patients included in the study) (p=0.620). Among patients, CSF TDP-43 levels were significantly correlated with age (r=0.50, p=0.0003) and ALS Functional Rating Scale (ALSFRS-R) (r=-0.49, p=0.021). ALS patients with CSF TDP-43 levels above compared with those below the median value (4.76 ng/mL), had a reduced survival probability (p=0.016).

Conclusions

High levels of CSF TDP-43 may be associated with a rapid progression of disease and with a reduced survival.

Authors/Disclosures
Chiara Zecca, MD (Ente ospedaliero cantonale) PRESENTER	Prof. Zecca has nothing to disclose.
	No disclosure on file
Rosa Capozzo	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Giancarlo Logroscino, MD, PhD, F�鶹��ýӳ�� (University of Bari)	Dr. Logroscino has nothing to disclose.

�鶹��ýӳ��

�鶹��ýӳ��